Publicaciones en las que colabora con Francisco Marin Ortuño (63)

2023

  1. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

    Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323

2022

  1. Contact pathway in surgical and transcatheter aortic valve replacement

    Frontiers in Cardiovascular Medicine, Vol. 9

2020

  1. Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation

    Mayo Clinic Proceedings, Vol. 95, Núm. 11, pp. 2360-2369

  2. Pilot study on the role of circulating mirnas for the improvement of the predictive ability of the 2mace score in patients with atrial fibrillation

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-11

  3. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: The Murcia AF project

    Thrombosis and Haemostasis, Vol. 120, Núm. 8, pp. 1200-1207

2019

  1. Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under Vitamin K antagonists

    QJM, Vol. 112, Núm. 3, pp. 183-188

  2. Murcia atrial fibrillation project II: Protocol for a prospective observational study in patients with atrial fibrillation

    BMJ Open, Vol. 9, Núm. 12

  3. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores

    Stroke, Vol. 50, Núm. 6, pp. 1372-1379

2018

  1. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA 2 DS 2 -VASc and HAS-BLED scores using multiple biomarkers

    Annals of Medicine, Vol. 50, Núm. 1, pp. 26-34

  2. A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials

    Mayo Clinic Proceedings, Vol. 93, Núm. 8, pp. 1065-1073

  3. Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality

    International Journal of Clinical Practice, Vol. 72, Núm. 3

  4. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in ‘real-world’ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients

    International Journal of Cardiology, Vol. 254, pp. 125-131

  5. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation

    European Journal of Clinical Investigation, Vol. 48, Núm. 6

  6. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED

    American Heart Journal, Vol. 197, pp. 27-34

  7. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol

    Clinical Therapeutics, Vol. 40, Núm. 1, pp. 114-122

  8. Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project

    Journal of General Internal Medicine, Vol. 33, Núm. 6, pp. 847-854

2017

  1. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients

    Thrombosis and Haemostasis, Vol. 117, Núm. 7, pp. 1448-1454

  2. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?

    Scientific Reports, Vol. 7

  3. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation

    Scientific Reports, Vol. 7, Núm. 1

  4. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and abc-bleeding risk scores: The murcia atrial fibrillation project

    Thrombosis and Haemostasis, Vol. 117, Núm. 10, pp. 1848-1858